Added to YB: 2025-11-07
Pitch date: 2025-11-05
CMPS [bullish]
COMPASS Pathways plc
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
Market Cap
$570.9M
Pitch Price
N/A
Price Target
10.40
Dividend
N/A
EV/EBITDA
-2.77
P/E
-2.17
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The Illegal Drug That Might Fix Depression - COMPASS Pathways plc
CMPS: British biotech's synthetic psilocybin COMP360 hit Phase 3 primary endpoint for treatment-resistant depression w/ -3.6 MADRS improvement vs placebo at 6wks. FDA Breakthrough Therapy designation. Q1 2026 durability data catalyst. Risk-weighted $10.40 target vs $6.50 (+60% upside).
Read full article (6 min)